Soleno Therapeutics (SLNO) Gross Margin (2015 - 2026)

Soleno Therapeutics' (SLNO) quarterly Gross Margin came in at 98.73% in Q1 2026, little changed on a QoQ basis from 99.06% in Q4 2025.

Soleno Therapeutics (SLNO) Gross Margin (2015 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has 5 years of Gross Margin data on file, last reported at 98.73% in Q1 2026.

On a quarterly basis, Gross Margin changed N/A year-over-year to 98.73% in Q1 2026; TTM through Mar 2026 was 98.63%, a N/A change from a year earlier, with the FY2025 full-year figure at 98.58%, changed N/A from the prior year.
Gross Margin for Q1 2026 stood at 98.73%, roughly flat from 99.06% in the prior quarter.
Over the last five years, Gross Margin for SLNO reached as high as 99.06% in Q4 2025 and fell as low as 97.87% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	88.95%
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	86.85%
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	91.79%
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	90.68%
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Soleno Therapeutics	874.25 Mn	618.67 Mn	93.41 Mn	98.73%

Download Data